Medical journals and healthcare reports

FDA Approves Illumina's TruSight Oncology Comprehensive for Bayer and Lilly Therapies

Aug 27, 2024, 02:01 PM

The U.S. Food and Drug Administration (FDA) has approved Illumina's TruSight Oncology Comprehensive assay, a cancer biomarker test designed to rapidly match patients to targeted therapies. This test includes two companion diagnostics and is specifically approved as a companion diagnostic (CDx) for kinase inhibitors from pharmaceutical companies Bayer and Lilly. The assay identifies patients with NTRK gene fusions who may benefit from Bayer's Vitrakvi (larotrectinib) and those with RET fusion-positive cancers who may benefit from Lilly's Retevmo (selpercatinib).